# A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

> **NCT05067140** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 152 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** ARV-766 Part A&B
- **DRUG:** ARV-766 + Abiraterone Part C&D

## Key facts

- **NCT ID:** NCT05067140
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-02
- **Primary completion:** 2027-05-25
- **Final completion:** 2027-05-25
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05067140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05067140, "A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05067140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*